The use of Tocilizumab in COVID-19 critically ill patients with renal impairment: a multicenter, cohort study

The use of Tocilizumab in COVID-19 critically ill patients with renal impairment: a multicenter, cohort study

AbstractTocilizumab (TCZ) is recommended in patients with COVID-19 who require oxygen therapy or ventilatory support. Despite the wide use of TCZ, little is known about its safety and effectiveness in patients with COVID-19 and renal impairment. Therefore, this study evaluated the safety and effecti...

Full description

Bibliographic Details
Main Authors: Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Aisha Alharbi, Ali F. Altebainawi, Shatha A. Aldkheel, Sarah G. Alotaibi, Ramesh Vishwakarma, Hanan Alshareef, Samiah Alsohimi, Mashael AlFaifi, Abdulrahman Al Shaya, Haifa A. Alhaidal, Raghad M. Alsubaie, Hessah Alrashidi, Khalid J. Albarqi, Dalal T. Alangari, Reem M. Alanazi, Noora M. Altaher, Hasan M. Al-Dorzi
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Renal Failure
Subjects:
Tocilizumab
renal impairment
covid-19
critically ill
acute kidney injury
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2023.2268213

Internet

https://www.tandfonline.com/doi/10.1080/0886022X.2023.2268213

Similar Items